News and Announcements
ASMX announce Bartercard Founder, Wayne Sharpe, as an advisor
- Published November 01, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- ASMX announce the founder of Australian business, Bartercard, Wayne Sharpe, as an advisor.
- During his time as a Chief Executive and Chairman of Bartercard, the company facilitated over US $40 billion in trade.
- ASMX CEO, said the company are excited to on board him into the company.
ASMX are pleased to announce the founder of Australian business, Bartercard, Wayne Sharpe, as an advisor.
Mr Sharpe founded Bartercard, during his time as Chief Executive and Chairman of Bartercard, the company facilitated over US$40 billion in trade and had 136 offices worldwide.
Mr Sharpe won multiple awards during his time Director on the Global Barter association IRTA.
ASMX have been working on a blockchain solution that aims to connect the world’s lending communities.
Mr Sharpe has developed a number of exchange for equities, commodities and carbon trading.
Wayne Sharpe said: “ASMX will become an essential resource for lending communities throughout the world.”
About AMSX Ltd
P2P lending has become a large business in a very short space of time, and is set to continue its growth. However, the successful scaling of any market is ‘Access’ and ‘Liquidity’.
ASMX will provide a decentralised blockchain based solution for trading private debt originated by existing and an expanding online lending network that will be accessible to qualifying retail lenders globally.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
